Anwar Giryes1, Hani Oweira2, Meinrad Mannhart3, Michael Decker4, Omar Abdel-Rahman5,6. 1. Swiss Medical Clinic, Zürich, Switzerland. 2. Gastrointestinal Tumor Zentrum, Zürich, Switzerland. 3. Department of Oncology, Center of Zug, Zug, Switzerland. 4. Oncology Department, Zentrum für Integrative Onkologie, Zürich, Switzerland. 5. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 6. Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Abstract
BACKGROUND: The current study sought to explore the potential clinical, epidemiological and genetic differences between early-onset gastric cancer (E-gastric cancer: defined as 20-39 years) and traditional-onset gastric cancer (T-gastric cancer: defined as ≥40 years). METHODS: Datasets from the following sources were searched: Surveillance, Epidemiology and End Results database [2000-2014], Behavioral Risk Factor Surveillance Survey and the cancer genome atlas (TCGA). Clinicopathological characteristics, trends, and genetic findings were compared between E-gastric cancer and T-gastric cancer. Moreover, correlations with relevant risk factors were sought after. RESULTS: A total of 95,323 gastric cancer patients were identified in the period from 2000 to 2014. While T-gastric cancer was decreasing during the study period (-1.4; P<0.05), E-gastric cancer was stable during the study period. E-gastric cancer is less prevalent in males (51.1% vs. 61.0%; P<0.0001), and white patients (68.9% vs. 71.4%; P<0.0001). E-gastric cancer patients usually present with poorly differentiated histology (55.3% vs. 48.0%; P<0.0001) as well as more aggressive histological subtypes (e.g., diffuse histology or linitis plastica). No difference can be detected with regards to risk factor correlations between E-gastric cancer and T-gastric cancer. Only four patients with E-gastric cancer were available in the provisional TCGA dataset at the time of the study. CONCLUSIONS: E-gastric cancer is a potentially distinct disease entity with specific clinicopathological and trend patterns compared to conventional T-gastric cancer. Further studies are needed to explore the potential etiologic basis as well as to investigate the clinical consequences of this distinction. The impact of this distinction on minority populations requires further assessment as well.
BACKGROUND: The current study sought to explore the potential clinical, epidemiological and genetic differences between early-onset gastric cancer (E-gastric cancer: defined as 20-39 years) and traditional-onset gastric cancer (T-gastric cancer: defined as ≥40 years). METHODS: Datasets from the following sources were searched: Surveillance, Epidemiology and End Results database [2000-2014], Behavioral Risk Factor Surveillance Survey and the cancer genome atlas (TCGA). Clinicopathological characteristics, trends, and genetic findings were compared between E-gastric cancer and T-gastric cancer. Moreover, correlations with relevant risk factors were sought after. RESULTS: A total of 95,323 gastric cancer patients were identified in the period from 2000 to 2014. While T-gastric cancer was decreasing during the study period (-1.4; P<0.05), E-gastric cancer was stable during the study period. E-gastric cancer is less prevalent in males (51.1% vs. 61.0%; P<0.0001), and white patients (68.9% vs. 71.4%; P<0.0001). E-gastric cancer patients usually present with poorly differentiated histology (55.3% vs. 48.0%; P<0.0001) as well as more aggressive histological subtypes (e.g., diffuse histology or linitis plastica). No difference can be detected with regards to risk factor correlations between E-gastric cancer and T-gastric cancer. Only four patients with E-gastric cancer were available in the provisional TCGA dataset at the time of the study. CONCLUSIONS: E-gastric cancer is a potentially distinct disease entity with specific clinicopathological and trend patterns compared to conventional T-gastric cancer. Further studies are needed to explore the potential etiologic basis as well as to investigate the clinical consequences of this distinction. The impact of this distinction on minority populations requires further assessment as well.
Authors: Samantha Hansford; Pardeep Kaurah; Hector Li-Chang; Michelle Woo; Janine Senz; Hugo Pinheiro; Kasmintan A Schrader; David F Schaeffer; Karey Shumansky; George Zogopoulos; Teresa Almeida Santos; Isabel Claro; Joana Carvalho; Cydney Nielsen; Sarah Padilla; Amy Lum; Aline Talhouk; Katie Baker-Lange; Sue Richardson; Ivy Lewis; Noralane M Lindor; Erin Pennell; Andree MacMillan; Bridget Fernandez; Gisella Keller; Henry Lynch; Sohrab P Shah; Parry Guilford; Steven Gallinger; Giovanni Corso; Franco Roviello; Carlos Caldas; Carla Oliveira; Paul D P Pharoah; David G Huntsman Journal: JAMA Oncol Date: 2015-04 Impact factor: 31.777
Authors: Shaila J Merchant; Joseph Kim; Audrey H Choi; Virginia Sun; Joseph Chao; Rebecca Nelson Journal: Gastric Cancer Date: 2016-02-29 Impact factor: 7.370
Authors: Robert L Grossman; Allison P Heath; Vincent Ferretti; Harold E Varmus; Douglas R Lowy; Warren A Kibbe; Louis M Staudt Journal: N Engl J Med Date: 2016-09-22 Impact factor: 91.245
Authors: Jung Ho Shim; Kyo Young Song; Hae Myung Jeon; Cho Hyun Park; Lindsay M Jacks; Mithat Gonen; Manish A Shah; Murray F Brennan; Daniel G Coit; Vivian E Strong Journal: Ann Surg Oncol Date: 2014-03-06 Impact factor: 5.344
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Manzoor A Dhobi; Khursheed Alam Wani; Fazl Qadir Parray; Rouf A Wani; Mohd Lateef Wani; G Q Peer; Safiya Abdullah; Imtiyaz A Wani; Muneer A Wani; Mubashir A Shah; Natasha Thakur Journal: Int J Surg Oncol Date: 2013-12-07
Authors: Jun Zou; Wan Qin; Lin Yang; Lulu Wang; Yu Wang; Jianfeng Shen; Wei Xiong; Shiying Yu; Shumei Song; Jaffer A Ajani; Shiaw-Yih Lin; Gordon B Mills; Xianglin Yuan; Jianying Chen; Guang Peng Journal: Am J Cancer Res Date: 2020-11-01 Impact factor: 6.166
Authors: M Aronson; C Swallow; A Govindarajan; K Semotiuk; Z Cohen; P Kaurah; L Velsher; I Ambus; K Buckley; C Forster-Gibson; W S Meschino; A Blumenthal; R H Kim; S Brar Journal: Curr Oncol Date: 2020-05-01 Impact factor: 3.677
Authors: Michael LaPelusa; Chan Shen; Erin A Gillaspie; Christopher Cann; Eric Lambright; A Bapsi Chakravarthy; Michael K Gibson; Cathy Eng Journal: Cancers (Basel) Date: 2022-07-26 Impact factor: 6.575